Enzon to Release Third Quarter 2010 Earnings on Tuesday, November 2, 2010
BRIDGEWATER, N.J., Oct 26, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended September 30, 2010, on Tuesday, November 2, 2010. The Company will also conduct a conference call that day at 4:00 p.m. ET to discuss results and highlights of the third quarter 2010.
All interested parties may access the call with the following information:
Domestic Dial-In Number: (877) 561-2748
International Dial-In Number: (720) 545-0044
Access Code: Enzon
The call will also be available via live audio webcast on the Enzon website, by going to the 'Calendar of Events' page in the 'Investors' section. Listeners should go to the website at least fifteen minutes before the event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, November 2, 2010 at approximately 8:00 pm Eastern Time (ET) and end on Tuesday, November 9, 2010 at approximately 11:59 pm Eastern Time (ET). It may be accessed using the following information:
Domestic Dial-In Number: (800) 642-1687
International Dial-In Number: (706) 645-9291
Conference I.D.: 21014444
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative medicines for patients with cancer. Enzon's drug development programs utilize several approaches, including its cutting-edge proprietary customized linker-enhanced PEGylation technology and mRNA antagonists using the Locked Nucleic Acid (LNA) technology. Enzon receives a royalty revenue stream from licensing arrangements for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.
SOURCE: Enzon Pharmaceuticals, Inc.
Andrea Rabney, 212-600-1902
Copyright Business Wire 2010